A federal court in Massachusetts has granted Pfizer and BioNTech’s motion to put on hold Moderna’s lawsuit over alleged ...

Ratings for BioNTech (NASDAQ:BNTX) were provided by 11 analysts in the past three months, showcasing a mix of bullish and bearish perspectives. Summarizing their recent assessments, the table below ...

After nearly two years of legal back and forth, Pfizer and its German partner BioNTech have won a brief reprieve in their ...

There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on BioNTech SE (BNTX – Research Report), ...

Three years after receiving BioNTech’s cancer vaccine in a phase 1 trial, patients with a difficult-to-treat type of ...

BioNTech stock tumbled to its lowest point in three years Wednesday after the Covid vaccine maker reported light fourth-quarter sales and profit, and delivered lackluster 2024 guidance.

The American pharmaceutical company – which was due to set up a Covid-19 vaccine production line on the continent – is ...

Shares of BioNTech SE sank toward a more than two-year low Wednesday, after the Germany-based biotechnology company reported fourth-quarter results that fell sharply below expectations ...

BioNtech-Pfizer has promised to deliver up to 75 million more coronavirus vaccine doses to the EU in the second quarter of 2021, the company's head Sierk Poetting said in a statement on Monday.

BioNTech SE ADR (NASDAQ: BNTX) has a price-to-earnings ratio that is above its average at 20.97x. The stock has a 36-month beta value of 0.24. Opinions on the stock are mixed, with 0 analysts rating ...

BioNTech is a Germany-based biotechnology company that focuses on developing cancer therapeutics, including individualized immunotherapy, as well as vaccines for infectious diseases, including covid.

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...